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We report optical-resolution photoacoustic microscopy (OR-PAM) for in vivo imaging of amyloid plaques in
an Alzheimer’s disease mouse model. Validation using conventional fluorescence microscopy and multipho-
ton microscopy shows that OR-PAM has sufficient sensitivity and spatial resolution to identify amyloid
plaques in living brains. In addition, with dual-wavelength OR-PAM, the three-dimensional morphology of
amyloid plaques and the surrounding microvasculature are imaged simultaneously through a cranial win-
dow without angiographic contrast agents. OR-PAM, capable of providing both exogenous molecular contrast
and endogenous hemoglobin contrast, has the potential to serve as a new technology for in vivo microscopic
observations of cerebral plaque deposits. © 2009 Optical Society of America
OCIS codes: 170.3880, 170.5120, 170.6900.Amyloid-, the primary constituent of senile plaques,
is hypothesized to play a major role in the pathogen-
esis of Alzheimer’s disease (AD), but the underlying
mechanisms are still elusive. Recent advances in es-
tablished clinical imaging modalities have permitted
noninvasive imaging of amyloid deposits in patients
[1]. However, the neuropathologic changes in AD are
microscopic, and subtle changes due to disease pro-
gression or treatment may be undetectable by such
clinical instruments because of their low spatial reso-
lutions. Multiphoton microscopy, a commercially
available laser-scanning microscopy technique, al-
lows imaging of amyloid plaques with high sensitiv-
ity and submicrometer resolution in animal models
[2]. However, its applications are limited by the in-
ability to image through the intact skull, thereby re-
quiring cranial window preparations.
Here, we report the first application of optical-
resolution photoacoustic microscopy (OR-PAM) to-
ward imaging amyloid plaques in an AD transgenic
mouse model. OR-PAM images of Congo-red-stained
brain sections from these mice were virtually identi-
cal to fluorescence images. Moreover, in vivo OR-PAM
images through a cranial window also showed high
correlation with observations by multiphoton micros-
copy. As a new technology for in vivo amyloid plaque
imaging, OR-PAM provides both the exogenous mo-
lecular contrast from the amyloid-specific Congo red
dye and the endogenous absorption contrast from he-
moglobin, enabling simultaneous visualization of ce-
rebral microvasculature without using angiographic
dye.
Figure 1 shows a schematic of the OR-PAM system
for intravital amyloid plaque imaging. To maximize
the imaging sensitivity, optical illumination and ul-
trasonic detection in our OR-PAM system are config-
ured confocally by an acoustic-optical beam splitter
[3]. The beam splitter is nearly transparent to the op-
0146-9592/09/243899-3/$15.00 ©tical illumination, but the oil–glass surface at the di-
agonal reflects almost all the ultrasonic signals to a
75 MHz ultrasonic transducer [V2022 (BC), Olympus
NDT] attached to the vertical side of the bottom
prism. The near-diffraction-limited optical focusing
achieved by a commercial microscope objective
(RMS4, Thorlabs) determines the 5 m lateral res-
olution of OR-PAM. An acoustic lens (NA 0.46) is at-
tached to the bottom of the beam splitter and im-
mersed in a water tank to collect photoacoustic
signals. A window is opened in the bottom of the wa-
ter tank and sealed with an ultrasonically and opti-
cally transparent polyethylene membrane to expose
the imaging site. For simplification, the water tank is
not shown in Fig. 1. Two-dimensional mechanical
scanning of the animal along the transverse plane, in
combination with time-resolved ultrasonic detection,
provides volumetric resolution. Hence, no depth
scanning is necessary.
To compare and validate OR-PAM with established
fluorescence microscopy for imaging of amyloid
Fig. 1. (Color online) Schematic of the optical-resolution
photoacoustic microscope for amyloid plaque imaging. OR-
PAM imaging and multiphoton imaging were performed
through a cranial window preparation (inset).
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10-month-old APPswe/PS1dE9 mouse (APP/PS1, The
Jackson Laboratory) was cover slipped and examined
using a fluorescence microscope (BX50, Olympus)
equipped with a MicroFire monochrome microscope
digital CCD camera (Optronics) under Rhodamine
excitation 496–540 nm. By measuring red fluores-
cence 520–625 nm, amyloid plaques were detected
in APP/PS1 brain sections [Fig. 2(A)]. A 11 mm re-
gion of interest (ROI) (enclosed by the red dashed box
in Fig. 2(A), and replotted in Fig. 2(B) for better com-
parison) was imaged by OR-PAM using a 523 nm
wavelength [Fig. 2(C)]. All amyloid plaques visual-
ized using conventional fluorescence microscopy were
observed with OR-PAM as well, suggesting that OR-
PAM has the sensitivity and spatial resolution re-
quired to image amyloid plaques [a few representa-
tive plaques are paired up in Figs. 2(B) and 2(C) for
comparison]. The main features of amyloid plaques
in the two images were virtually identical (the corre-
lation coefficient was calculated to be 0.95 based on
both plaque size and location).
To examine the plaque imaging capability of OR-
PAM in living mice, OR-PAM images were directly
compared with the images acquired by multiphoton
microscopy. A 10-month-old APP/PS1 mouse was in-
jected with Congo red through the cisterna magna to
label amyloid plaques in vivo. Twenty-four hours af-
ter injection, an open-skull cranial window covered
by a plastic coverslip was created over the parietal
cortex, and dye labeling was confirmed by conven-
tional fluorescence imaging [Fig. 3(A)]. An ROI [en-
closed by the red dashed box in Fig. 3(A)] containing
a variety of amyloid plaques and blood vessels was
selected for both dual-wavelength OR-PAM imaging
and multiphoton imaging (LSM 510 META NLO sys-
tem, Zeiss). Two-photon fluorescence was generated
with 800 nm excitation (Chameleon Ti:sapphire la-
ser, Coherent) and detected in the spectral range of
565–615 nm. A maximum-intensity-projection image
[Fig. 3(B)] was generated by a z-stack image series
acquired from the cranial window surface to a depth
of 200 m into the cortex. The incremental z-step
distance was 10 m under a 10 water-immersion
Fig. 2. (Color online) In vitro imaging of a Congo-red-
stained brain section from a 10-month-old APP/PS1 mouse;
(A) entire hippocampus imaged using conventional fluores-
cence microscopy; (B) region of interest selected from the
boxed area in (A); (C) same region of interest imaged by
OR-PAM for comparison. Arrows, plaques. Scale bar in (A)
applies to all three parts.objective (NA 0.33, Zeiss). For the dual-wavelength
OR-PAM imaging, optical wavelengths of 570 nm
[Fig. 3(C)] and 523 nm [Fig. 3(D)] were selected to
differentiate the photoacoustic signals generated by
hemoglobin and Congo-red-labeled amyloid plaques.
Imaging depths of amyloid plaques and blood vessels
were quantified to be 230 m and 450 m from the
cortical surface, respectively. The absorption of
Congo red at 523 nm is 6 times higher than that at
570 nm [4]; however, the absorption of hemoglobin
differs by only 1.4 times [5]. Moreover, at each wave-
length, the optical absorption coefficients of oxy- and
deoxy-hemoglobin are nearly equal, so the blood pho-
toacoustic signals reflect the total hemoglobin con-
centration regardless of the blood oxygenation level.
Fig. 3. (Color online) In vivo brain imaging of a Congo-red-
injected 10-month-old APP/PS1 mouse through a cranial
window. (A) Exposed cortical brain region imaged using
conventional fluorescence microscopy through the cranial
window. The region of interest marked by a red dashed box
was imaged by multiphoton microscopy in (B), and OR-
PAM at 570 nm in (C) and 523 nm in (D). (E) The processed
dual-contrast OR-PAM image, where amyloid plaques are
colored green (online) and blood vessels are colored red (on-
line) [volumetric visualization is available online as (Media
1)]. Arrows, plaques. Scale bar in (B) applies to parts
(B)–(E).Based on these two characteristics, the photoacoustic
December 15, 2009 / Vol. 34, No. 24 / OPTICS LETTERS 3901image taken at 523 nm was linearly scaled to equal-
ize the blood vessel signals with their counterparts
taken at 570 nm, and then the two mutually normal-
ized images were subtracted pixelwise to eliminate
the blood signals and isolate the Congo-red-labeled
amyloid plaques. Upon separating the distributions
of the hemoglobin and the amyloid plaques, they
were pseudocolored differently for clear visualization
in both the maximum-amplitude-projection image
[Fig. 3(E)] and the 3D movie (Media 1). Images ac-
quired using OR-PAM and multiphoton microscopy
were directly compared, revealing excellent correla-
tion in plaque distribution [arrows, Figs. 3(B), 3(D),
and 3(E)]. A few small plaques visualized using mul-
tiphoton microscopy [Fig. 3(B)] were not detected by
the OR-PAM system [Fig. 3(E)], most likely owing to
the limited signal-to-noise ratio caused by the nonop-
timized excitation wavelength for Congo red detec-
tion and by the interference from the strong blood ab-
sorption. It should be noted that the imaged plaque
sizes are slightly different as measured by the two
imaging modalities. This likely reflects differences in
imaging contrast and sensitivity between the two
techniques; however, since each plaque can serve as
its own control for time-lapsed imaging, measures of
relative plaque growth are expected to be similar.
Although the current configuration of OR-PAM has
successfully demonstrated the ability to image amy-
loid plaques in vivo, transcranial imaging (through
an intact skull) is certainly more attractive for mini-
mally invasive monitoring of AD progression and
drug efficacy. OR-PAM has already been shown to be
capable of imaging individual capillaries through in-
tact skulls in living adult mice [6]. Thus in vivo tran-
scranial OR-PAM imaging of amyloid plaques, which
are similar to or larger than capillaries, is highly
likely with further optimization of imaging param-
eters and improvements in the optical absorption of
amyloid-specific dyes, as indicated below.
One possible improvement would take advantage
of the fact that the absorption spectrum of Congo red
peaks at 500–510 nm, where hemoglobin experiences
a local absorption valley [4,5]. Downshifting the opti-
cal illumination wavelength of OR-PAM to 500–510
nm (not available in our current laser system) will in-
crease the contrast between hemoglobin and Congo
red by at least a factor of 4, which will help differen-
tiate between amyloid plaques and blood vessels. An-
other possible improvement is to modify the current
acoustic detection mechanism to avoid the unneces-
sary transformation of the photoacoustic signals from
p waves to sv waves and to apply an ultrasonic anti-
reflection coating to the acoustic lens. Still another
improvement is suggested by the Fourier analysis of
our transcranial mouse brain imaging data, which
shows that decreasing the center frequency of the ul-
trasonic transducer from current 75 MHz to 40 MHz
is expected to further increase the detected photoa-
coustic signals by twofold at the expense of spatial
resolution.
Besides technical improvements to the OR-PAM
system, developing amyloid-specific dyes absorbingat the near-IR (NIR) optical window of biological tis-
sues 700–800 nm would be expected to further en-
hance in vivo amyloid plaque imaging [7]. Tissue
scattering and absorption within the NIR range are
greatly reduced compared with that in the visible
spectrum. Working in the NIR region with the aid of
highly specific amyloid dyes will allow deeper tissue
penetration and provide higher contrast between the
targeted amyloid plaques and the surrounding tis-
sues.
Advances in the above aspects will likely allow OR-
PAM imaging of amyloid plaques through an intact
mouse skull. This noninvasive imaging capability
will eliminate the influence of the cranial window
preparations on the underlying brain tissues. Recent
studies suggest that invasive cranial window prepa-
rations may adversely influence underlying brain tis-
sue behavior [8,9]. Furthermore, imaging through an
intact skull would greatly expand the available re-
gions for imaging, thereby reducing the numbers of
animals needed to quantify plaque growth. Such a
model would be very attractive as an in vivo screen
for drug development.
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